Merck & Co Inc (MRK)

MRK on New York Consolidated

57.75USD
27 Mar 2015
Change (% chg)

$0.15 (+0.26%)
Prev Close
$57.60
Open
$57.83
Day's High
$58.23
Day's Low
$57.63
Volume
8,523,494
Avg. Vol
11,302,031
52-wk High
$63.62
52-wk Low
$52.49

MRK

Chart for MRK

About

Merck & Co., Inc., is a health care company. The Company delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company’s operations are principally managed on a products basis and are... (more)

Overall

Beta: 0.34
Market Cap(Mil.): $163,905.59
Shares Outstanding(Mil.): 2,838.19
Dividend: 0.45
Yield (%): 3.12

Financials

  MRK Industry Sector
P/E (TTM): 14.10 40.31 40.78
EPS (TTM): 4.10 -- --
ROI: 14.50 16.86 16.19
ROE: 24.22 17.40 17.04
Search Stocks

Merck KGaA's deputy chief Oschmann set to become CEO: Manager Magazin

FRANKFURT - Germany's Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources.

20 Mar 2015

Merck KGaA's deputy chief Oschmann set to become CEO - Manager Magazin

FRANKFURT, March 20 - Germany's Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources.

20 Mar 2015

Esperion drug lowers cholesterol in patients taking statins

- Esperion Therapeutics Inc said its experimental drug lowered LDL or "bad" cholesterol levels in patients who were already on statins, the current standard of care.

17 Mar 2015

Merck expects to be denied approval for sugammadex injection again

- Merck & Co Inc said it expects its long-delayed drug to reverse the effects of anesthesia to be denied U.S. approval after U.S. regulators said they need to conduct more site inspections related to a study of the drug.

13 Mar 2015

UPDATE 1-Merck expects to be denied approval for sugammadex injection again

March 13 - Merck & Co Inc said it expects its long-delayed drug to reverse the effects of anesthesia to be denied U.S. approval after U.S. regulators said they need to conduct more site inspections related to a study of the drug.

13 Mar 2015

Merck expects to be denied approval for sugammadex injection again

March 13 - Merck & Co Inc said it expected to be denied U.S. approval for its sugammadex injection, after the U.S. Food and Drug Administration said it would conduct additional site inspections related to a study of the drug.

13 Mar 2015

Merck cancer drug is first approved under UK early access scheme

LONDON - Merck & Co's cancer drug Keytruda, which works by boosting the immune system but has yet to be licensed in Europe, is the first medicine to be made available to patients in Britain under a new early access scheme.

11 Mar 2015

Merck cancer drug is first approved under UK early access scheme

LONDON, March 11 - Merck & Co's cancer drug Keytruda, which works by boosting the immune system but has yet to be licensed in Europe, is the first medicine to be made available to patients in Britain under a new early access scheme.

11 Mar 2015

Guinea to start final trials of Ebola vaccines this week

LONDON/GENEVA - Final stage trials of an Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday.

05 Mar 2015

UPDATE 2-Guinea to start final trials of Ebola vaccines this week

* WHO says effective Ebola shot could be a "game-changer" (Adds details of "ring vaccination" plans, quotes)

05 Mar 2015

Competitors

Earnings vs. Estimates

Search Stocks